Recent Updates
Recently added Catalysts
RADX Positive Sentiment Score: 70/100

Dosing begins in Phase 1 Pancreatic Imaging Study of RAD 301

Friday, March 1, 2024 1 min read
Key Takeaway: Radiopharm Theranostics has announced the initiation of dosing in a Phase 1 clinical study for RAD 301, aimed at improving pancreatic imaging. This study marks a significant step forward in the company's research efforts. The focus on pancreatic imaging is crucial, given the challenges in diagnosing pancreatic conditions effectively.

Market Sentiment Analysis

POSITIVE FACTORS

  • Dosing has commenced in a Phase 1 study, indicating progress.
  • The study focuses on pancreatic imaging, a critical area in oncology.
  • The initiation of this trial may lead to advancements in diagnostic techniques.

Full Press Release Details

• Announcements
• Price Sensitive
• March 1, 2024
Loading Viewer…

More Announcements & Updates

• Announcements
• October 17, 2023
• Announcements
• November 26, 2021
• Announcements
• September 20, 2022
• Announcements
• December 22, 2023

Radiopharm Theranostics Doses First Patient in Phase 1/2a ClinicalStudy of BetaBart (RV-01)

Zacks SCR Analysts Share Their Best Small-Cap Research Ideas for 2026

Radiopharm Theranostics Provides Positive Clinical Updates Across Four Programs

CLINICAL UPDATE AND CAPITAL RAISING OCTOBER 20th, 2025

Radiopharm Theranostics Receives IND approval from US FDA to Initiate Phase I Therapeutic Clinical Study to target B7H3 with Betabart (RV-01)

Dr. Oliver Sartor Appointed to Radiopharm Scientific Advisory Board

• RAD Presentation June 2026
• Zacks Small-Cap Research 2026
• RAD Presentation March 2026
• Radiopharm Theranostics Doses First Patient in Phase 1/2a ClinicalStudy of BetaBart (RV-01)
• Zacks SCR Analysts Share Their Best Small-Cap Research Ideas for 2026
• Zacks Small-Cap Research

Frequently Asked Questions

What is RAD 301?

RAD 301 is a compound being studied for its potential in pancreatic imaging.

What phase is the RAD 301 study currently in?

The RAD 301 study has begun dosing in Phase 1.

Why is pancreatic imaging important?

Pancreatic imaging is crucial for the effective diagnosis of pancreatic conditions.

Who is conducting the RAD 301 study?

The study is being conducted by Radiopharm Theranostics.

Tags: RADX Viatris Investor Conferences Healthcare Radiopharm Theranostics RAD 301 pancreatic imaging Phase 1 study clinical trial
Last updated: Mar 1, 2024